Markers that have been clinically introduced in colon cancer include RAS mutations that exclude anti-EGFR therapy and microsatellite instability (MSI) as a marker of good prognosis in stage II colon cancer. The gene discussed is EGFR; the disease is malignant colon neoplasm.